{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:29:27Z","timestamp":1740126567406,"version":"3.37.3"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Advisory Board"},{"name":"International Aspirin Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,14]]},"DOI":"10.1093\/eurheartj\/ehab106","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T21:02:21Z","timestamp":1612904541000},"page":"1061-1062","source":"Crossref","is-referenced-by-count":2,"title":["A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19"],"prefix":"10.1093","volume":"42","author":[{"given":"Massimo","family":"Volpe","sequence":"first","affiliation":[{"name":"Cardiology, Sapienza University of Rome, Sant\u2019Andrea Hospital, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[{"name":"Pharmacology, Catholic University School of Medicine, Rome, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,28]]},"reference":[{"key":"2021031422092648900_ehab106-B1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"2021031422092648900_ehab106-B2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/ehjcvp\/pvaa030","article-title":"Might renin-angiotensin system blockers play a role in the COVID-19 pandemic?","volume":"6","author":"Battistoni","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2021031422092648900_ehab106-B3","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"2021031422092648900_ehab106-B4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijcard.2020.07.041","article-title":"Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: a new challenge overcome?","volume":"321","author":"Volpe","year":"2020","journal-title":"Int J Cardiol"},{"key":"2021031422092648900_ehab106-B5","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"2021031422092648900_ehab106-B6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/HYPERTENSIONAHA.120.15324","article-title":"Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension","volume":"76","author":"Iaccarino","year":"2020","journal-title":"Hypertension"},{"key":"2021031422092648900_ehab106-B7","first-page":"30558","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"year":"2019","key":"2021031422092648900_ehab106-B8"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/11\/1061\/36598231\/ehab106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/11\/1061\/36598231\/ehab106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T22:09:36Z","timestamp":1615759776000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/11\/1061\/6154411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,28]]},"references-count":8,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,2,28]]},"published-print":{"date-parts":[[2021,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab106","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"type":"print","value":"0195-668X"},{"type":"electronic","value":"1522-9645"}],"subject":[],"published-other":{"date-parts":[[2021,3,14]]},"published":{"date-parts":[[2021,2,28]]}}}